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quested. The sponsor policy related to data sharing was not
taken into account. Some sponsors agree to share only se-
lectedstudies.However, thepurposeof thestudywas toevalu-
ate the amount of available data, regardless of whether a trial
was not listed because of company policy or for another rea-
son. In addition, only 1 repository was evaluated.
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COMMENT&RESPONSE
Prenatal Vitamin D andOffspringWheezing
To the EditorDrLitonjua andcolleagues reported the results of
a randomized clinical trial investigating the effect of prenatal
supplementation with vitamin D on asthma andwheezing in
young offspring.1 The study provides an example of the prob-
lemswith so-called “statistical significance” and the interpre-
tationofPvalueswith reference to anarbitrary threshold. The
authors estimated that high-dose vitamin D given in preg-
nancywasassociatedwitha reduced riskof thecoprimaryout-
comeof recurrentwheeze (hazard ratio [HR],0.8 [95%CI,0.6-
1.0]), with an associated P value of .051.
The conclusion of the article emphasized that this result
“did notmeet statistical significance” (the P value was >.05).
The implication is that, had the P value been just .002 lower
(ie,P = .049), theauthorsmighthavepresented their final con-
clusion with a different emphasis, noting “statistical signifi-
cance,” and the trial resultsmight havebeen interpretedmore
positively, with a conclusion that prenatal supplementation
with vitamin D had a beneficial effect.
Yet the statistical meanings of both P = .051 and P = .049
are similar: if the null hypothesiswere true (no real treatment
effect), and the trial were repeated many times, a difference
between the treatment groups at least as large as observed
would be expected about once every 20 times due to chance
variation alone.
The problems with arbitrarily dichotomizing results into
statistically significant or nonsignificant have been noted for
many years, and major journals now expect authors to pre-
sent CIs and exact P values, offsetting some of the problems
with this approach.2-4 Litonjua and colleagues rightly pointed
out that their study may have lacked power and that the CIs
did not preclude a clinically important protective effect of
supplementation. Despite this, the focus on a binary notion
of statistical significance still persists, andwe think that it col-
ors the interpretationof results in anoverly simplisticway.We
suggest that such terminology be avoided, with P values in-
terpreted as a continuous measure of strength of evidence
against the null hypothesis.
With this approach, this trial might have been inter-
preted as providing some, but not strong, evidence of a pro-
tective effect of supplementationduring pregnancy on recur-
rent wheeze in offspring, and the range of possible clinically
relevant benefits might have been better emphasized in key
parts of the article. This interpretation would be similar with
P = .051 or P = .049.
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To the Editor A study of vitamin D supplementation in preg-
nancy found the incidence of asthma and recurrent wheeze
in offspring at age 3 years was lower by 6.1% compared with
placebo.1However, the6.1%differencewasnot statistically sig-
nificant and the trial was negative, but a reader would never
know that reading the abstract.
The trialwasdesigned todetect a 25% reduction in the in-
cidence of asthma and recurrentwheeze in the first 3 years of
life in the supplementedgroup,which is notmentioned in the
abstract. The study concluded that it may have been under-
powered.Thiswasanegative trial. It appears tohavebeenwell
done, the sample sizewaswell thought out, andpatientswere
adherent. Why then would the authors present these results
as anything but negative and imply that more research is
needed to examine this issue?
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In Reply Dr Bhaskaran and colleagues suggest that the inter-
pretation of our study should be less dependent on the
P value of .051, while Drs Merenstein and D’Amico suggest it
should be more strict. We agree with Bhaskaran and col-
leagues that the 6.1% lower incidence of asthma and recur-
rent wheeze in the offspring with prenatal vitamin D supple-
mentation may be better understood by considering the 95%
CI.1 The relative risk reduction was 20% (HR, 0.8) and the CI
suggested that the effect of the intervention is likely to lie
between a 40% reduction and no reduction (95% CI, 0.6-1.0).
However, a misconception is that the true effect can lie with
equal likelihood throughout the estimated CI, when in fact it
lies with a greater likelihood around the 20% estimate than
the extremes of the CI distribution.1
Merenstein and D’Amico are incorrect in that the abstract
clearly states that the 6.1% absolute reduction was reported
as not significant and the P value was presented, although
the uncertainty in the reduction was also expressed. As
Bhaskaran and colleagues suggest, the efficacy of an inter-
vention should not be judged solely on the P value.2 This
misuse of the P value has long been the subject of warnings
by statisticians3 and is addressed by a statement by the
American Statistical Association.4
WedisagreewithMerenstein andD’Amico in their sugges-
tion thatno further studies areneededon the issueofwhether
vitaminD supplementation inpregnancy canprevent asthma
or recurrentwheezing in the childbecause thePvaluewasnot
below an arbitrary threshold. We remind them that our trial
was done on a cohort at high risk of asthma and on amultira-
cial cohort.
Thus, caution should be exercised in making sweeping
statements about the effects of vitamin D. Because of these
and other uncertainties discussed above and because of the
growing realization that nutrient trials are different from
drug trials, our study could have been designed in a better
way. Nutrient trials are different from most other trials
because the population is already exposed to the nutrient
and individuals have circulating levels depending on the
baseline intake of this nutrient, as Heaney5 has pointed out.
As seen in our trial, levels of vitamin D at entry were not the
same in all participants, and the response to the dose of
vitamin D may be different depending on the initial circulat-
ing levels. Thus, basal nutrient status must be measured.
Other suggested guidelines are that the intervention must
be large enough to change nutrient status; that the change
in nutrient status must be measured and recorded; that the
hypothesis tested must be that a change in nutrient status
produces the effect of interest; and that conutrient status
must also be optimized. Unfortunately, these guidelines
were published after our trial started, and additional studies
that account for the issues in these guidelines are needed
before it can be truly known whether vitamin D supplemen-
tation taken during pregnancy can prevent asthma or recur-
rent wheeze in offspring.
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Characteristics of Patients DyingWith Cancer
in Developed Countries
To the EditorAcross-national study1 founddifferences in 7de-
veloped nations in the place of death, health care utilization,
and hospital expenditures for patients dying with cancer, a
finding that might be surprising but corresponds with com-
parable studies.2
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